Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/25/2025

Sedation Management in Parkinson's Disease

Introduction to Sedation Challenges

  • Parkinson's disease patients have increased sensitivity to medications that block dopamine receptors, which can worsen motor symptoms 1
  • The use of certain sedatives can risk worsening motor symptoms in Parkinson's disease patients 1, 2
  • Sedation in Parkinson's disease patients also carries a potential for cognitive impairment and delirium 3

First-Line Sedation Options

  • The American Academy of Sleep Medicine recommends quetiapine as a first-line option for sedation in Parkinson's disease patients, starting at a dose of 25 mg orally, due to its lower risk of extrapyramidal side effects 1
  • Quetiapine is effective for sedation and managing psychosis in Parkinson's disease patients, with advantages including less likelihood of causing extrapyramidal side effects than other antipsychotics 1, 3
  • Immediate-release melatonin is recommended for mild sedation needs, starting at 3 mg, with advantages including minimal impact on motor symptoms and suitability for older patients 2

Medications to Avoid or Use with Caution

  • The American Academy of Sleep Medicine advises against the use of haloperidol and other typical antipsychotics in Parkinson's disease patients due to the high risk of worsening parkinsonian symptoms 1
  • Benzodiazepines should be used with extreme caution in Parkinson's disease patients due to risks including increased cognitive impairment, higher fall risk, and potential for paradoxical excitation 1, 3, 5, 6

Special Considerations

  • For REM sleep behavior disorder in Parkinson's disease patients, immediate-release melatonin (3-15 mg) is conditionally recommended, with clonazepam (0.25-0.5 mg) considered with caution due to side effects 2
  • For delirium in Parkinson's disease patients, non-pharmacological interventions should be maximized first, and benzodiazepines should be avoided as initial treatment 3

Decision Algorithm

  • Quetiapine is the first choice for sedation in Parkinson's disease patients, starting at 25 mg orally 1
  • Immediate-release melatonin is an alternative for mild sedation needs, starting at 3 mg 2
  • Rivastigmine may be considered for patients with cognitive impairment and REM sleep behavior disorder 2
  • Low-dose, short-acting benzodiazepines may be used as a last resort with extreme caution when benefits clearly outweigh risks 3, 5

REFERENCES

2

management of rem sleep behavior disorder: an american academy of sleep medicine clinical practice guideline. [LINK]

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2023

3

palliative care version 1.2016. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

4

palliative care version 1.2016. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2016